Role of biochemical markers of bone turnover as prognostic indicator of successful osteoporosis therapy.

Abstract

Most of the currently available anti-osteoporosis medications promptly and significantly influence the rate of bone turnover. Biochemical markers of bone turnover now provide a high sensitivity to change, allowing the detection of these bone turnover changes within a couple of weeks. Since the anti-fracture efficacy of inhibitors of bone resorption or stimulators of bone formation appears to be largely independent of baseline bone turnover, biochemical markers do not appear to play a significant role in the selection of one particular drug, for an individual patient. However, there are consistent data showing that short-term changes in biochemical markers of bone turnover may be significant predictors of future changes in bone mineral density or fracture reduction, hence suggesting that bone turnover markers play a significant role in the monitoring of anti-osteoporosis therapy.

• Authors: Jean-Yves Reginster, Julien Collette, Audrey Neuprez, Brigitte Zegels, Rita Deroisy, Olivier Bruyere
• Journal: Bone (Bone) Vol. 42 Issue 5 Pg. 832-6 (May 2008) ISSN: 8756-3282 [Print] United States
• PMID: 18316258 (Publication Type: Editorial)

Chemical References

• Biomarkers
• Bone Density Conservation Agents

Topics

• Biomarkers (analysis, blood, urine)
• Bone Density (drug effects)
• Bone Density Conservation Agents (pharmacology, therapeutic use)
• Bone Remodeling (drug effects)
• Clinical Trials as Topic
• Female
• Humans
• Middle Aged
• Osteoporosis, Postmenopausal (diagnosis, drug therapy, metabolism)
• Prognosis